Henrietta Lacks was a 31-year-old Black woman whose cervical cancer cells were taken without her knowledge or consent at Johns Hopkins Hospital in 1951, and those cells went on to become one of the most important tools in modern biomedical research. The ethical failures surrounding HeLa cells, as they came to be known, forced a reckoning with how science treats human tissue, patient autonomy, and the communities most vulnerable to exploitation. What happened to Lacks and her family did not just reveal problems; it catalyzed concrete changes in consent law, privacy protections, and the governance of biological specimens that continue to evolve today.
What Happened at Johns Hopkins in 1951
Henrietta Lacks sought treatment for cervical cancer at Johns Hopkins, one of the few major hospitals in the Baltimore area that treated Black patients during segregation. During her treatment, a physician removed a sample of her tumor tissue and sent it to researcher George Gey’s laboratory without asking her permission. This was not unusual for the era. No federal regulations required informed consent for the use of patient tissue in research, and the practice of collecting samples from patients, particularly those in public wards or from marginalized communities, was routine. The atmosphere of racial inferiority theories, centuries of slavery, and biased educational processes had led to widespread medical and scientific abuse of African Americans, including unethical experimentation and overutilization as research subjects.1PubMed Central. Race, medicine, and health care in the United States: a historical survey
Lacks died of her cancer in October 1951. She never learned what had been done with her cells. Her family would not find out for more than two decades.
Why HeLa Cells Behaved Like No Other
What made Lacks’s cells extraordinary was their refusal to die. Human cells taken from the body and placed in a lab dish typically divide a limited number of times before they stop. Lacks’s cancer cells did not follow that pattern. They divided aggressively and continuously, producing a stable, self-renewing line that researchers could grow in virtually unlimited quantities.
The key to this immortality lies in the biology of her cancer. Lacks’s tumor was caused by a particularly aggressive strain of human papillomavirus, HPV 18, which had integrated its genetic material into her cells. The virus produced two proteins, known as E6 and E7, that effectively disabled the cell’s normal brakes on growth. Research has shown that continuous expression of both E6 and E7 is required for cervical carcinoma cells like HeLa to keep proliferating; when either protein is suppressed, the cells lose their ability to divide and begin to age or die.2PubMed Central. Endogenous human papillomavirus E6 and E7 proteins differentially regulate proliferation, senescence, and apoptosis in HeLa cervical carcinoma cells This combination of viral hijacking and cellular resilience gave researchers something they had been chasing for years: a human cell line that could be grown reliably, shipped between laboratories, and used as a standardized experimental platform.
The Science HeLa Cells Made Possible
The first and arguably most famous application of HeLa cells was in developing the polio vaccine. In the early 1950s, Jonas Salk needed massive quantities of human cells to grow and test the poliovirus. Tuskegee University, a historically Black institution, played a central role in the mass production and distribution of HeLa cells that made large-scale polio vaccine testing feasible.3PubMed Central. Development of the polio vaccine: a historical perspective of Tuskegee University’s role in mass production and distribution of HeLa cells The irony is hard to miss: a Black woman’s cells, taken without consent, were mass-produced at a Black university to help eradicate a disease that terrified the nation, yet neither Lacks nor her family received any recognition or compensation at the time.
Over the following decades, HeLa cells became the workhorse of cell biology. They were used in research on cancer, HIV, gene mapping, toxicology, and the effects of radiation, among many other fields. Scientists have used them to study how viruses enter and replicate inside human cells, to test the safety of drugs before human trials, and to understand the basic mechanics of cell division. As recently as 2021, HeLa cells engineered to express the receptor that SARS-CoV-2 uses to infect human cells were part of a screening pipeline that tested a large drug-repurposing library for potential COVID-19 treatments.4Nature Communications. Drug repurposing screens identify chemical entities for the development of COVID-19 interventions More than 70 years after their origin, the cells remain active research tools.
Consent and the Absence of It
The central ethical violation in the Lacks story is straightforward: no one asked her. There was no informed consent process, no disclosure that her tissue would be used for research, and no opportunity for her to refuse. When the cells proved scientifically valuable, no one contacted her family. When HeLa cells became a commercial product distributed to laboratories worldwide, no compensation flowed to the people whose DNA they carried.
This was not technically illegal in 1951. The concept of informed consent for research existed in limited forms after the Nuremberg trials, but it had not been codified into U.S. federal regulations governing domestic research. Patients at institutions like Johns Hopkins, especially those who were poor, Black, or both, had little practical power to question what happened to tissue removed during treatment. The Lacks case is so often discussed alongside the Tuskegee syphilis study because both illustrate how medical institutions exploited Black Americans under the cover of accepted practice, and both left scars on community trust that persist today.1PubMed Central. Race, medicine, and health care in the United States: a historical survey
Moore v. Regents and the Question of Ownership
The Lacks case was not the only time a patient’s cells were turned into a commercial product without their consent. In a case that became one of the most important legal precedents in this area, a man named John Moore was treated for hairy-cell leukemia at the University of California-Los Angeles Medical Center. His physician, David Golde, advised Moore to have his spleen removed. Moore was asked for permission to contribute to medical research and explicitly refused. Despite that refusal, portions of his excised spleen were used by Golde and colleagues to develop a commercially valuable cell line from Moore’s immune cells. UCLA applied for and was granted a patent on the cell line, listing Golde and a colleague as the inventors.5Indian Journal of Medical Ethics. Patenting of human genetic material v. bioethics: revisiting the case of John Moore v. Regents of the University of California
Moore sued. The California Supreme Court ruled in 1990 that he did not have property rights over his discarded cells, though it did find that his physician had breached a duty of informed consent by not disclosing the commercial interest in his tissue. The decision left a frustrating gap: patients had a right to be told what would happen with their biological material, but once it was removed from their body, they lost legal claim to it. That gap has shaped how tissue-ownership disputes have been handled ever since, and it is part of why the Lacks family had so few legal tools available to them for decades.
How the Lacks Case Reshaped Research Rules
The ethical abuses that came to light in the 1960s and 1970s, including the Tuskegee syphilis study and the growing awareness of unconsented tissue use, led to sweeping regulatory changes. The Belmont Report, published in 1979, established three core ethical principles for human subjects research: respect for persons, beneficence, and justice. Those principles were operationalized through the Federal Policy for the Protection of Human Subjects, commonly called the Common Rule, which was finalized in 1991. The Common Rule recognized that special attention was needed for assessments of risk experienced by socially vulnerable groups.6PubMed Central. The creation of the Belmont Report and its effect on ethical principles: a historical study
These regulations fundamentally changed how researchers could obtain and use human biological material. Institutional review boards became gatekeepers. Informed consent documents became standard. But the rules still contained exceptions. Even under the Common Rule, certain residual clinical biospecimens and health data could be reused without individual consent if an ethics committee approved the intended use, if a committee waived the authority of another regulation, or if the biospecimens and data were appropriately de-identified. A review of regulations across multiple countries found that about half of the identified regulations and norms emphasized the importance of consent or authorization when reusing residual clinical biospecimens for non-clinical purposes, but the rest relied on these institutional workarounds.7PubMed Central. Regulations and Norms for Reuse of Residual Clinical Biospecimens and Health Data In other words, the system improved enormously after Lacks’s era, but it never fully closed the gap between patient expectations and institutional practice.
The Genome Publication Controversy
In 2013, a new ethical crisis brought the Lacks story back into public focus. A European research group published the complete genome sequence of HeLa cells. While the data was scientifically valuable, it also contained genetic information that was traceable to Henrietta Lacks and, by extension, her living descendants. This made the privacy implications immediate and personal: anyone with the right expertise could examine the sequence and learn things about the family’s genetic predispositions.
The publication prompted a public outcry, and researchers began analyzing how genomic identifiability functions as a specific data issue, particularly in cases like HeLa where the cell line is tied to a known individual.8PubMed Central. Post-identifiability in changing sociotechnological genomic data environments The genome was initially made freely available in public databases. After negotiations with the Lacks family, the National Institutes of Health reached an agreement in August 2013 that placed the genomic data under controlled access. Researchers who wanted to use the HeLa genome sequence would have to apply to an NIH panel, and two members of the Lacks family were given seats on that panel. It was the first time the family had any formal role in governing how Henrietta Lacks’s biological material was used.
The genome controversy illustrated a problem that did not exist in 1951 and that even the Common Rule did not anticipate. De-identification, the standard tool for protecting research subjects’ privacy, does not work the same way with genomic data. A genome is inherently identifying. As sequencing becomes cheaper and databases grow, the assumption that removing a name from a tissue sample protects the donor becomes increasingly unreliable.
Medical Mistrust That Outlasts the Science
The Lacks case is not just a historical footnote. It is part of a living legacy of medical mistrust among Black Americans. The unconsented taking of Lacks’s cells, combined with atrocities like the Tuskegee syphilis study, has contributed to enduring skepticism of the medical and scientific community among Black Americans that continues to affect clinical research participation and health disparities.9PubMed Central. Henrietta Lacks and America’s dark history of research involving African Americans
This mistrust has real consequences. Lower participation in clinical trials means that treatments are tested on less diverse populations, which can lead to therapies that work less well or less predictably in the communities that were excluded. It also means that public health campaigns, from organ donation drives to vaccine rollouts, face steeper resistance in communities with long institutional memories of being used rather than served. When COVID-19 vaccines became available in 2020 and 2021, some of the hesitancy in Black communities was explicitly linked to the Lacks story and Tuskegee. The connection was not abstract. People cited specific historical examples of abuse when explaining why they did not trust that the system had changed enough.
The Lawsuit and the Question of Compensation
For decades, the Lacks family received nothing while HeLa cells generated enormous commercial value. Biotechnology companies sold the cells to laboratories around the world. In 2021, the descendants of Henrietta Lacks sued a well-known biotechnology company for the profits it made from the HeLa cell line.10Oxford Academic (Journal of Law and the Biosciences). Who would own the HeLa cell line if the Henrietta Lacks case happened in present-day South Africa? The case was settled in 2023, though the terms were not publicly disclosed. Other companies were also named in subsequent legal actions.
The lawsuit raised a question that the Moore decision left unanswered: even if patients do not legally own their excised cells, should they or their families share in the profits when those cells become the foundation of a multi-billion-dollar industry? The legal landscape remains fragmented. Different countries take different approaches, and even within the United States, the rules differ depending on whether you are talking about tissue collected during routine clinical care, tissue donated to a biobank, or tissue obtained through a formal research protocol. The Lacks family’s settlement may have resolved one dispute, but it did not create a precedent that automatically applies to the next case.
Dynamic Consent and the Push for Better Models
One of the more promising developments to come out of the broader ethical reckoning is the concept of dynamic consent. Traditional informed consent is a one-time event: you sign a form, and the researcher proceeds. Dynamic consent uses digital platforms to let research participants make ongoing, granular choices about how their data and specimens are used. Participants can consent to some aspects of the research but not others, update their preferences over time, and specify which types of data access by third parties are acceptable to them.11PubMed Central. Dynamic Consent: a potential solution to some of the challenges of modern biomedical research
This approach addresses one of the core failures in the Lacks case: the total absence of donor control. It also addresses a subtler problem that persists under current regulations. Even when patients give broad consent for their tissue to be used in “future research,” they often have no idea what that research might involve. A blood sample given for a heart disease study could end up in a genetic database used for forensic purposes or sold to a pharmaceutical company. Dynamic consent platforms let donors stay in the loop and adjust their decisions as circumstances change. The model is not yet standard, but it has gained traction in biobank governance and genomics research, particularly in Europe.
The Contamination Problem
HeLa cells created an entirely different kind of scientific problem that nobody anticipated. Because the cells grow so aggressively, they can easily take over other cell cultures in a laboratory. If a single HeLa cell contaminates a dish of, say, liver cells being used in a separate experiment, the HeLa cells will outcompete the liver cells and eventually replace them entirely. The researcher may not realize this has happened, and the results of their experiments will actually reflect HeLa cell behavior, not the cells they think they are studying.
This problem was first detected in the late 1960s. Through the work of geneticist Stanley Gartler, it became possible to detect contamination between cell lines of the same species, and several such contaminations involving HeLa cells were reported in the journal Nature in 1968.12PubMed Central. The ghosts of HeLa: How cell line misidentification contaminates the scientific literature The scope of the problem turned out to be enormous. Hundreds of cell lines used in thousands of published studies were later found to be contaminated by or entirely replaced with HeLa cells. This meant that a significant body of published research was built on false assumptions about which cells were actually being studied. Journals and funding agencies have since introduced cell line authentication requirements, but the contaminated literature remains a lingering problem that researchers still encounter.
What the Public Conversation Gets Wrong
Rebecca Skloot’s 2010 book, The Immortal Life of Henrietta Lacks, did more than any academic paper to bring the story to public attention. But the media conversation that followed the book’s publication had a notable blind spot. Analysis of the coverage found that media discussion generated by Skloot’s book focused narrowly on informed consent, which may have limited the ability of ethicists and advocates to draw attention to other important issues, including donor control over specimens, compensation for commercial use, patenting of human biological material, and privacy.13PubMed Central. Bioethics in popular science: evaluating the media impact of The Immortal Life of Henrietta Lacks on the biobank debate
Informed consent is a genuine ethical issue, but treating it as the whole story misses the structural questions. Even if Lacks had signed a consent form in 1951, would that have covered the commercial sale of her cells to thousands of laboratories? Would it have authorized the publication of her genome? Would it have entitled her family to any share of the profits? Consent is a necessary starting point, not a comprehensive ethical framework. The broader questions about ownership, profit-sharing, community benefit, and genetic privacy are harder to resolve, and they remain largely unresolved even as the technology that raises them continues to advance.
HeLa Cells and Racial Justice in Science
There is a dimension of the Lacks story that does not reduce to consent forms or legal rulings. Henrietta Lacks was a Black woman treated at a segregated institution in the Jim Crow South. The exploitation of her cells was not an isolated event but part of a documented pattern in which African Americans were disproportionately subjected to medical and scientific abuse, used as teaching material and experimental subjects, and denied the benefits of the medical advances their bodies helped create.1PubMed Central. Race, medicine, and health care in the United States: a historical survey Fixing the rules going forward is necessary. But the Lacks family and many advocates have argued that addressing the historical harm matters too, not just as a symbolic gesture but as a material step toward rebuilding the trust that was broken.
The 2013 NIH agreement and the 2023 legal settlement were steps in that direction, though how far they go depends on whom you ask. The broader question of whether communities harmed by past research abuses deserve systemic reparations, beyond case-by-case settlements, is one that bioethics as a field is only beginning to grapple with seriously. The Lacks case gave it a human face and a name. Whether that visibility translates into lasting structural change is still being determined.